Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

Blood (2025) 146 (Supplement 1): 4583.

https://doi.org/10.1182/blood-2025-4583

Published: 2025

Journal Articles

Long-term outcomes of syngeneic transplantation in multiple myeloma: Valuable legacy or obsolete option? a study from the chronic malignancies working party of the EBMT

Blood (2025) 146 (Supplement 1): 6357.

https://doi.org/10.1182/blood-2025-6357

Published: 2025

Journal Articles

Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT

Blood (2025) 146 (Supplement 1): 375.

https://doi.org/10.1182/blood-2025-375

Published: 2025

Journal Articles

Minimal residual disease-guided venetoclax plus rituximab for patients with previously untreated chronic lymphocytic leukemia (VERITA PALG-CLL5): primary endpoint analysis of the prospective, multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 5675.

https://doi.org/10.1182/blood-2025-5675

Published: 2025

Journal Articles

Unsupervised proteomic and metabolomic longitudinal serum profiling of anti-CD19 CAR-T cell therapy recipients reveals clinically distinct groups

Jaromir Tomasik, Kannathasan Thetchinamoorthy, Diana Wierzbicka, Agnieszka Tomaszewska, Piotr Kacprzyk, Joanna Drozd-Sokołowska, Rafał Machowicz, Mariusz Ratajczak, Magdalena Kucia, Grzegorz Basak

Blood (2025) 146 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2025-5926

Published: 2025

Journal Articles

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Blood (2025) 145 (26): 3139–3152.

https://doi.org/10.1182/blood.2024027287

Published: 2025

Includes: Supplemental data

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Blood (2025) 145 (18): 1987–2001.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2024-203487

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4939.

https://doi.org/10.1182/blood-2024-193963

Published: 2024

Journal Articles

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Blood (2024) 144 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2024-194695

Published: 2024

Journal Articles

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Blood (2024) 144 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2024-201076

Published: 2024

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 600.

https://doi.org/10.1182/blood-2024-198075

Published: 2024

Journal Articles

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Blood (2024) 144 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2024-193992

Published: 2024

Journal Articles

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

Blood (2024) 144 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2024-200237

Published: 2024

Journal Articles

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2024-208144

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Blood (2024) 144 (Supplement 1): 4949.

https://doi.org/10.1182/blood-2024-203009

Published: 2024

Journal Articles

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Blood (2024) 144 (4): 445–456.

https://doi.org/10.1182/blood.2023022273

Published: 2024

Includes: Supplemental data

Journal Articles

Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2023-184945

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT

Blood (2023) 142 (Supplement 1): 708.

https://doi.org/10.1182/blood-2023-174385

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

Long-term outcomes of syngeneic transplantation in multiple myeloma: Valuable legacy or obsolete option? a study from the chronic malignancies working party of the EBMT

Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT

Minimal residual disease-guided venetoclax plus rituximab for patients with previously untreated chronic lymphocytic leukemia (VERITA PALG-CLL5): primary endpoint analysis of the prospective, multicenter, Phase 2 trial

Unsupervised proteomic and metabolomic longitudinal serum profiling of anti-CD19 CAR-T cell therapy recipients reveals clinically distinct groups

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis

Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques

The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma

Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only